But it is suggested that the usage of CK-18 in routine clinical practice is premature.8 Current studies have documented CK18 as convenient biomarker for making the diagnosis of the NAFLD. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatotic liver disease.